What is the difference between AMANTADINE and LEVODOPA?

AMANTADINE is a Other and LEVODOPA is a Parkinson's Agent. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Can AMANTADINE and LEVODOPA be used for the same conditions?

Both medications are prescribed for overlapping indications including Indications and Usage Amantadine Hydrochloride Oral Solution and postencephalitic parkinsonism. Always verify with your prescriber and the current FDA label before switching.

Is Amantadine the same as Inbrija?

No. Amantadine (AMANTADINE) and Inbrija (LEVODOPA) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, AMANTADINE or LEVODOPA?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from AMANTADINE to LEVODOPA?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

AMANTADINE vs LEVODOPA

Compare AMANTADINE (Amantadine) and LEVODOPA (Inbrija) — clinical data, side effects, and patient experiences.

AMANTADINE

Amantadine · Other

How it works

Other agent

Approved for

Indications and Usage Amantadine Hydrochloride Oral Solution

postencephalitic parkinsonism

amantadine hydrochloride is less effective than levodopa

(-)-3-(3

OralTablet

LEVODOPA

Inbrija, Sinemet · Parkinson's Agent

How it works

12.1 Mechanism of Action Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be ...

Approved for

See full prescribing information

Respiratory (inhalation)Tablet

Quick Comparison

AMANTADINELEVODOPA

Drug Class

Other

Parkinson's Agent

Route

Oral

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

AMANTADINE

Falls

>10%

Drug Not Working

1-10%

Fatigue

1-10%

Dizziness

1-10%

Tremor

1-10%

Nausea

1-10%

Weakness

1-10%

Condition Worsened

0.1-1%

LEVODOPA

Drowsiness

0.1-1%

Weakness

0.1-1%

Drug Not Working

>10%

Falls

>10%

Tremor

1-10%

Dizziness

1-10%

Nausea

1-10%

Cough

1-10%

FDA Warnings

AMANTADINE

WARNINGS Deaths : Deaths have been reported from overdose with amantadine hydrochloride
Deaths due to drug accumulation (overdose) have been reported in patients with renal impairment, who were prescribed higher than recommended doses of amantadine hydrochloride for their level of renal function (see DOSAGE AND ADMINISTRATION ; Dosage of Impaired Renal Function and OVERDOSAGE )
Suicide Attempts : Suicide attempts, some of which have been fatal, have been reported in patients treated with amantadine hydrochloride, many of whom received short courses for influenza treatment or prophylaxis
Because of the possibility of serious adverse effects, caution should be observed when prescribing amantadine hydrochloride to patients being treated with drugs having CNS effects, or for whom the potential risks outweigh the benefit of treatment

LEVODOPA

5 WARNINGS AND PRECAUTIONS May cause falling asleep during activities of daily living ( 5
1 ) Avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal-emergent hyperpyrexia and confusion ( 5
Although many of these patients reported somnolence, some reported no warning signs (sleep attack) and believed that they were alert immediately prior to the event
Before initiating treatment with INBRIJA, advise patients about the potential to develop drowsiness and ask about factors that may increase the risk for somnolence with INBRIJA such as the concomitant use of sedating medications and the presence of sleep disorders

Clinical Trial Data

No head-to-head clinical studies found for AMANTADINE vs LEVODOPA.

AMANTADINE vs LEVODOPA: What You Should Know

Key Differences

AMANTADINE is a Other, while LEVODOPA belongs to the Parkinson's Agent class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. AMANTADINE is administered via Oral, whereas LEVODOPA uses Respiratory (inhalation). Route of administration can affect onset of action and patient adherence.

Safety Considerations

AMANTADINE carries 4 FDA warnings. LEVODOPA carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

LEVODOPA vs PRAMIPEXOLE DIHYDROCHLORIDE→ENTACAPONE vs LEVODOPA→LEVODOPA vs RASAGILINE→LEVODOPA vs ROPINIROLE HYDROCHLORIDE→CARBIDOPA AND LEVODOPA vs LEVODOPA→LEVODOPA vs ROPINIROLE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

AMANTADINE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
LEVODOPA: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

AMANTADINE vs LEVODOPA

Compare AMANTADINE (Amantadine) and LEVODOPA (Inbrija) — clinical data, side effects, and patient experiences.

AMANTADINE

Amantadine · Other

How it works

Other agent

Approved for

Indications and Usage Amantadine Hydrochloride Oral Solution

postencephalitic parkinsonism

amantadine hydrochloride is less effective than levodopa

(-)-3-(3

OralTablet

LEVODOPA

Inbrija, Sinemet · Parkinson's Agent

How it works

12.1 Mechanism of Action Levodopa, the metabolic precursor of dopamine, crosses the blood-brain barrier and presumably is converted to dopamine in the brain. This is thought to be ...

Approved for

See full prescribing information

Respiratory (inhalation)Tablet

Quick Comparison

AMANTADINELEVODOPA

Drug Class

Other

Parkinson's Agent

Route

Oral

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

AMANTADINE

Falls

>10%

Drug Not Working

1-10%

Fatigue

1-10%

Dizziness

1-10%

Tremor

1-10%

Nausea

1-10%

Weakness

1-10%

Condition Worsened

0.1-1%

LEVODOPA

Drowsiness

0.1-1%

Weakness

0.1-1%

Drug Not Working

>10%

Falls

>10%

Tremor

1-10%

Dizziness

1-10%

Nausea

1-10%

Cough

1-10%

FDA Warnings

AMANTADINE

WARNINGS Deaths : Deaths have been reported from overdose with amantadine hydrochloride
Deaths due to drug accumulation (overdose) have been reported in patients with renal impairment, who were prescribed higher than recommended doses of amantadine hydrochloride for their level of renal function (see DOSAGE AND ADMINISTRATION ; Dosage of Impaired Renal Function and OVERDOSAGE )
Suicide Attempts : Suicide attempts, some of which have been fatal, have been reported in patients treated with amantadine hydrochloride, many of whom received short courses for influenza treatment or prophylaxis
Because of the possibility of serious adverse effects, caution should be observed when prescribing amantadine hydrochloride to patients being treated with drugs having CNS effects, or for whom the potential risks outweigh the benefit of treatment

LEVODOPA

5 WARNINGS AND PRECAUTIONS May cause falling asleep during activities of daily living ( 5
1 ) Avoid sudden discontinuation or rapid dose reduction to reduce the risk of withdrawal-emergent hyperpyrexia and confusion ( 5
Although many of these patients reported somnolence, some reported no warning signs (sleep attack) and believed that they were alert immediately prior to the event
Before initiating treatment with INBRIJA, advise patients about the potential to develop drowsiness and ask about factors that may increase the risk for somnolence with INBRIJA such as the concomitant use of sedating medications and the presence of sleep disorders

Clinical Trial Data

No head-to-head clinical studies found for AMANTADINE vs LEVODOPA.

AMANTADINE vs LEVODOPA: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.